.jpg?#)
Candel to focus on non-squamous lung cancer following new survival data
Candel Therapeutics said Wednesday that its viral immunotherapy prolonged survival of progressive lung cancer patients only marginally in a mid-stage trial. However, the data sparked plans for late-stage development in those with non-squamous disease, who ...
Candel Therapeutics said Wednesday that its viral immunotherapy prolonged survival of progressive lung cancer patients only marginally in a mid-stage trial. However, the data sparked plans for late-stage development in those with non-squamous disease, who ...
